Home
Search
Search Results
Previously Searched
3145 results found
Expand All
Apply All
3145 results found

Love biotech, love your heart
Good Day BIO Newsletter  •  February 14, 2024
Happy Valentine’s Day! On the day celebrating love—during American Heart Month—we look at new cardiovascular research and innovations that make us love biotech. Enjoy your chocolate today—because climate change is coming. (522 words, 2 minutes, 36 seconds)
Read More

A cure for the 'pill penalty'
Good Day BIO Newsletter  •  February 13, 2024
Today, a closer look at why Congress should pass the EPIC Act and end the “pill penalty,” and some ideas on how policy can encourage a more sustainable bioeconomy. (474 words, 2 minutes, 22 seconds)
Read More

AMR researcher brain drain
Good Day BIO Newsletter  •  February 12, 2024
A new report from the AMR Industry Alliance warns of researchers leaving the field of AMR, and a European Parliament vote cleared the way for potential legislation to ease regulation of some crops altered through “new genomic techniques (NGTs).” (608 words, 3 minutes, 2 seconds)
Read More

Thank You For Confirming
BIO Business Solutions

CEOs, Senators: Drug revenues drive U.S. innovation
Good Day BIO Newsletter  •  February 9, 2024
We recap what biopharma CEOs said on Capitol Hill yesterday, and the launch of a new cloud-based platform that would streamline information and data exchange between drug developers and regulators worldwide. (698 words, 3 minutes, 29 seconds)
Read More

Thank You For Subscribing

FDA Approvals & Clinical Development Pipeline
Industry Analysis Reports

BIO Board member talks IP on the Hill
Good Day BIO Newsletter  •  February 8, 2024
BIO Board member Eddie J. Sullivan testified on the Hill yesterday about the impact an expanded IP waiver would have on innovative biotechs like SAb Biotherapeutics—we have a recap, as well as yesterday’s House vote to prohibit the use of QALYs in federal programs. (532 words, 2 minutes, 39 seconds)
Read More

Comments to Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
Letters, Testimony & Comments  •  February 7, 2024
On behalf of its member companies and organizations, the Biotechnology Innovation Organization (“BIO”) extends its appreciation to NIST for considering these comments in response to the agency’s Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (the “draft framework”).  
Read More

BIO Comments to Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (NIST–2023–0008), 88 Fed. Reg. 85593
Letters, Testimony & Comments  •  February 7, 2024
On behalf of its member companies and organizations, the Biotechnology Innovation Organization (“BIO”) extends its appreciation to NIST for considering these comments in response to the agency’s Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (the “draft framework”).
Read More